Novel Chemiluminescent Immunoassay Detects Toxoplasma in Human Sera
|
By LabMedica International staff writers Posted on 26 Jul 2016 |
|
Image: The Centro XS³ LB 960 microplate luminometer (Photo courtesy of Berthold Technologies).
Toxoplasmosis is common disease in humans and animals caused by the protozoan parasite Toxoplasma gondii and while this disease in healthy people is usually asymptomatic, in congenital cases and immune deficient patients it can lead to serious pathological effects.
Currently, routine diagnosis of toxoplasmosis relies mainly on the use of various serological tests to detect specific antibodies in the serum samples of infected patients. The outcome of these tests depends on the antigen types and the methods of detection, and often the early recognition of the infection or precise distinction between phases of toxoplasmosis is difficult.
Scientists at the Gdansk University of Technology (Poland) developed new immunochemical reagents in the form of original chemiluminescence (CL) labels, which enabled them to perform the immunoglobulin G (IgG) chemiluminescent immunoassay (CLIA) tests for diagnosis of human toxoplasmosis. To assess the performance of novel immunochemical reagents in the CLIA assay, SAG2-GRA1-ROP1L chimeric protein for the detection of IgG specific antibodies was utilized. The latter was previously tested as diagnostic antigen in typical enzyme-linked immunosorbent assay (ELISA). The emission profiles were simultaneously measured over 3 to 30 second periods to collect at least 95% of the CL signal, using a Centro XS3 LB-960 microplate luminometer (Berthold Technologies, Bad Wildbad, Germany).
All of the sera used in the study were received from a routine toxoplasmosis screening. A total of 92 sera were analyzed, using commercial tests (Vidas Toxo-IgG II, Toxo-Screen DA, and Vidas Toxo-IgM; bioMérieux, Marcy l'Etoile. France) and divided into the two groups: group I (IgG positive and IgM positive or negative) included 47 sera from patients with toxoplasmosis and group II (IgG and IgM negative) consisted of 45 serum samples from seronegative individuals. The diagnostic usefulness of variously acridinium ester (AE)-labeled antibodies was tested on the same day. The scientists found that the assay with the participation of AE1 conjugate expressed greater ability to distinguish the sera from patients with T. gondii infection and healthy individuals.
The authors concluded that with the development and application of recombinant antigen (rAg) and recombinant antibody (rAb) technology as well as the use of a novel acridinium CL labels, CLIA approach can acquire a new dimension. However, further work is needed before this kind of immunoassay will be available for clinical purposes. The study was published online on May 24, 2016, in the journal Diagnostic Microbiology and Infectious Diseases.
Related Links:
Gdansk University of Technology
Berthold Technologies
bioMérieux
Currently, routine diagnosis of toxoplasmosis relies mainly on the use of various serological tests to detect specific antibodies in the serum samples of infected patients. The outcome of these tests depends on the antigen types and the methods of detection, and often the early recognition of the infection or precise distinction between phases of toxoplasmosis is difficult.
Scientists at the Gdansk University of Technology (Poland) developed new immunochemical reagents in the form of original chemiluminescence (CL) labels, which enabled them to perform the immunoglobulin G (IgG) chemiluminescent immunoassay (CLIA) tests for diagnosis of human toxoplasmosis. To assess the performance of novel immunochemical reagents in the CLIA assay, SAG2-GRA1-ROP1L chimeric protein for the detection of IgG specific antibodies was utilized. The latter was previously tested as diagnostic antigen in typical enzyme-linked immunosorbent assay (ELISA). The emission profiles were simultaneously measured over 3 to 30 second periods to collect at least 95% of the CL signal, using a Centro XS3 LB-960 microplate luminometer (Berthold Technologies, Bad Wildbad, Germany).
All of the sera used in the study were received from a routine toxoplasmosis screening. A total of 92 sera were analyzed, using commercial tests (Vidas Toxo-IgG II, Toxo-Screen DA, and Vidas Toxo-IgM; bioMérieux, Marcy l'Etoile. France) and divided into the two groups: group I (IgG positive and IgM positive or negative) included 47 sera from patients with toxoplasmosis and group II (IgG and IgM negative) consisted of 45 serum samples from seronegative individuals. The diagnostic usefulness of variously acridinium ester (AE)-labeled antibodies was tested on the same day. The scientists found that the assay with the participation of AE1 conjugate expressed greater ability to distinguish the sera from patients with T. gondii infection and healthy individuals.
The authors concluded that with the development and application of recombinant antigen (rAg) and recombinant antibody (rAb) technology as well as the use of a novel acridinium CL labels, CLIA approach can acquire a new dimension. However, further work is needed before this kind of immunoassay will be available for clinical purposes. The study was published online on May 24, 2016, in the journal Diagnostic Microbiology and Infectious Diseases.
Related Links:
Gdansk University of Technology
Berthold Technologies
bioMérieux
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS
Latest Technology News
- New Diagnostic System Achieves PCR Testing Accuracy
- DNA Biosensor Enables Early Diagnosis of Cervical Cancer
- Self-Heating Microfluidic Devices Can Detect Diseases in Tiny Blood or Fluid Samples
- Breakthrough in Diagnostic Technology Could Make On-The-Spot Testing Widely Accessible
- First of Its Kind Technology Detects Glucose in Human Saliva
- Electrochemical Device Identifies People at Higher Risk for Osteoporosis Using Single Blood Drop
- Novel Noninvasive Test Detects Malaria Infection without Blood Sample
- Portable Optofluidic Sensing Devices Could Simultaneously Perform Variety of Medical Tests
- Point-of-Care Software Solution Helps Manage Disparate POCT Scenarios across Patient Testing Locations
- Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents
- Breakthrough Test Detects Biological Markers Related to Wider Variety of Cancers
- Rapid POC Sensing Kit to Determine Gut Health from Blood Serum and Stool Samples
- Device Converts Smartphone into Fluorescence Microscope for Just USD 50
- Wi-Fi Enabled Handheld Tube Reader Designed for Easy Portability
Channels
Clinical Chemistry
view channel
3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more.jpg "Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)")
POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more
Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
The conventional methods for measuring free cortisol, the body's stress hormone, from blood or saliva are quite demanding and require sample processing. The most common method, therefore, involves collecting... Read more
Molecular Diagnostics
view channel
Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
Two studies have identified proteins in the blood that could potentially alert individuals to the presence of cancer more than seven years before the disease is clinically diagnosed. Researchers found... Read more (1)_1.jpg "Image: Ultrasound image of micro-histotripsy liberation of biomarkers in a tumor (Photo courtesy of Joy Wang and Pradyumna Kedarisetti)"){kind=small}
Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
Ultrasound imaging serves as a noninvasive method to locate and monitor cancerous tumors effectively. However, crucial details about the cancer, such as the specific types of cells and genetic mutations... Read more_1.jpg "Image: The innovative method to customize and strengthen DNA origami structure promises breakthroughs in medicine (Photo courtesy of Shutterstock)")
.jpg "Image: The QIAstat-Dx Respiratory Panel Plus has received U.S. FDA clearance (Photo courtesy of QIAGEN)")
Hematology
view channel
Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more
First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
Arboviruses represent an emerging global health threat, exacerbated by climate change and increased international travel that is facilitating their spread across new regions. Chikungunya, dengue, West... Read more
POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read moreImmunology
view channel.jpg "Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)")
AI Predicts Tumor-Killing Cells with High Accuracy
Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more
Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more
AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
Current strategies for matching cancer patients with specific treatments often depend on bulk sequencing of tumor DNA and RNA, which provides an average profile from all cells within a tumor sample.... Read more
Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read morePathology
view channel
Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues
Breast cancer remains a major cause of cancer-related mortality among women. Breast-conserving surgery (BCS), also known as lumpectomy, is the removal of the cancerous lump and a small margin of surrounding tissue.... Read more
AI Advancements Enable Leap into 3D Pathology
Human tissue is complex, intricate, and naturally three-dimensional. However, the thin two-dimensional tissue slices commonly used by pathologists to diagnose diseases provide only a limited view of the... Read more
New Blood Test Device Modeled on Leeches to Help Diagnose Malaria
Many individuals have a fear of needles, making the experience of having blood drawn from their arm particularly distressing. An alternative method involves taking blood from the fingertip or earlobe,... Read more
Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read moreTechnology
view channel
New Diagnostic System Achieves PCR Testing Accuracy
While PCR tests are the gold standard of accuracy for virology testing, they come with limitations such as complexity, the need for skilled lab operators, and longer result times. They also require complex... Read more
DNA Biosensor Enables Early Diagnosis of Cervical Cancer
Molybdenum disulfide (MoS2), recognized for its potential to form two-dimensional nanosheets like graphene, is a material that's increasingly catching the eye of the scientific community.... Read more
Self-Heating Microfluidic Devices Can Detect Diseases in Tiny Blood or Fluid Samples
Microfluidics, which are miniature devices that control the flow of liquids and facilitate chemical reactions, play a key role in disease detection from small samples of blood or other fluids.... Read more
Breakthrough in Diagnostic Technology Could Make On-The-Spot Testing Widely Accessible
Home testing gained significant importance during the COVID-19 pandemic, yet the availability of rapid tests is limited, and most of them can only drive one liquid across the strip, leading to continued... Read moreIndustry
view channel
Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
Unlike severe traumatic brain injury (TBI), mild TBI often does not show clear correlations with abnormalities detected through head computed tomography (CT) scans. Consequently, there is a pressing need... Read more
Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
Beckman Coulter Diagnostics (Brea, CA, USA) and MeMed BV (Haifa, Israel) have expanded their host immune response diagnostics partnership. Beckman Coulter is now an authorized distributor of the MeMed... Read more_1.jpg "Image: Thermo Fisher will distribute Bio-Techne products across Europe (Photo courtesy of 123RF)")
